LONDON, Jan 16 (Reuters) – Novo Nordisk’s Wegovy pill hit 3,071 U.S. prescriptions in the first four days after its launch, IQVIA data shared by analysts on Friday showed, as investors closely watch to see if the firm can ram home its first-mover advantage against rival Eli Lilly in a competitive weight-loss market.
The data reflects retail prescriptions for oral Wegovy, not those filled through the drugmaker’s online NovoCare Pharmacy, so actual prescription numbers will be higher, Barclays analysts said in a note.
(Reporting by Bhanvi Satija; Editing by Joe Bavier)
<
Leave a Reply